Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV

Trial Profile

Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Beclabuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2016 Results (n=30) presented at The International Liver Congress™ 2016
    • 08 Dec 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top